NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a blood pressure pill protect the liver? new trial investigates
Disease control OngoingThis study tests whether lisinopril, a drug typically used for high blood pressure, can slow liver scarring in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it can lower the risk of developing liver cancer. About 45 adults with advanced liver scarri…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC
-
New drug shows promise for fatty liver cirrhosis in early trial
Disease control OngoingThis study tests an experimental drug called efinopegdutide in 80 adults with liver scarring (cirrhosis) caused by metabolic dysfunction-associated steatohepatitis (MASH), a type of fatty liver disease. The goal is to see if the drug can reduce liver fat, inflammation, and scarri…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
Hidden liver risk in type 1 diabetes revealed by new study
Knowledge-focused OngoingThis study looked at 533 adults with type 1 diabetes to find out how many have nonalcoholic fatty liver disease (NAFLD) and serious liver scarring. Researchers used a special ultrasound and blood tests to check for liver problems without any needles or surgery. The goal is to ide…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Joslin Diabetes Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC